SynthesisFrontiers in public health2021
Appraisal of China's Response to the Outbreak of COVID-19 in Comparison With SARS.
Synthesis in Frontiers in public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Tuberculosis incidence and mortality trends in mainland China, 2004-2024: control program and elimination progress.Tropical medicine and health · 2026Article
- Biosafety status analysis and risk assessment of laboratories from 2021 to 2023 in Jiaxing, China.Frontiers in bioengineering and biotechnology · 2025Article
- Scoping review of countries' practices missed by health emergency preparedness and response quantitative tools: COVID-19 and Ebola response experiences.BMJ public health · 2024Article
- Impact of the COVID-19 pandemic on the conduct of non-COVID-19 clinical trials: protocol for a scoping review.BMJ open · 2023Article
- Moving toward a common goal via cross-sector collaboration: lessons learned from SARS to COVID-19 in Singapore.Globalization and health · 2022Article
- Knowledge Mapping Analysis of Public Health Emergency Management Research Based on Web of Science.Frontiers in public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, was first reported in Wuhan, China, in December 2019 and has since become a pandemic. The COVID-19 containment measures were comparable to those used with severe acute respiratory syndrome (SARS), although these were stricter and more organized, and were initiated earlier and on a larger scale. Based on the lessons learned from SARS, the Chinese government acted aggressively in response to COVID-19, through a unified and effective commanding system, using law-based and science-driven strategies, and coordinated deployment of medical resources. Additionally, the application of high-tech measures, traditional Chinese medicine, and hierarchical medical systems also played an important role in control measures. Despite the remarkable performance, the initial delay in response suggests that the coordination between public health and medical services, reserve and coordination of emergency materials, and capacity for disease control and prevention need to be strengthened.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.